本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Intellia Therapeutics Inc

9.48
+0.38504.23%
成交量:166.68萬
成交額:1,525.16萬
市值:9.81億
市盈率:-1.81
高:9.48
開:9.40
低:8.86
收:9.10
資料載入中...

公司資料

公司名字:
Intellia Therapeutics Inc
交易所:
NASDAQ
成立時間:
2014
員工人數:
403
公司地址:
40 Erie Street,Suite 130,Cambridge,Massachusetts,United States
郵編:
02139
電話:
傳真:
- -
簡介:
Intellia Therapeutics, Inc.於2014年5月在特拉華州註冊成立。該公司是一家領先的基因編輯公司,專註於利用最近開發的被稱為CRISPR/ Cas9的系統生物工具進行的獨特的、潛在治癒療法的發展。公司認為CRISPR/ Cas9技術具有通過單一療程永久編輯疾病相關的基因在人體內進行改造藥物的潛力。該公司打算利用其領先的科學專業知識、臨床開發經驗和知識產權地位解鎖CRISPR/ Cas9基因編輯廣泛的治療應用,發展有潛能的新一代治療產品。

董事

名稱
職位
Frank Verwiel
Chairman of the Board and Director
John M. Leonard
President and Chief Executive Officer and Director
Caroline D. Dorsa
Director
Fred Cohen
Director
Georgia Keresty
Director
Jean Francois Formela
Director
Jesse Goodman
Director
John F. Crowley
Director
Muna Bhanji
Director
William Chase
Director

股東

名稱
職位
John M. Leonard
President and Chief Executive Officer and Director
Glenn G. Goddard
Executive Vice President, Chief Financial Officer and Treasurer
David Lebwohl
Executive Vice President, Chief Medical Officer
Derek Hicks
Executive Vice President, Chief Business Officer
Eliana Clark
Executive Vice President, Chief Technology Officer
James Basta
Executive Vice President, General Counsel and Corporate Secretary
Laura Sepp Lorenzino
Executive Vice President, Chief Scientific Officer